Hope for Hard-to-Treat lymphoma: arthritis drug joins chemo in new trial
NCT ID NCT07494565
First seen Mar 30, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This study tests whether adding the arthritis drug celecoxib to standard chemotherapy (R-CHOP) works better than chemo alone for people with a specific, aggressive type of lymphoma (CD5-positive DLBCL). About 60 adults with newly diagnosed advanced disease will be randomly assigned to one of the two treatments. The main goal is to see if the combination leads to more complete remissions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.